O. S. Zatsarinnaya

O. S. Zatsarinnaya

Auto-generated profile, based on publicly available information

O. S. Zatsarinnaya

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2024 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
TST. V. Shamanskaya
T. V. Shamanskaya
DKDenis Kachanov
Denis Kachanov
NIN. S. Ivanov
N. S. Ivanov
LRL. L. Rabaeva
L. L. Rabaeva
M. Ya. YadgarovM. Ya. Yadgarov
M. Ya. Yadgarov
МЯМ. Я. Ядгаров
М. Я. Ядгаров
Monoclonal antibodies (mAbs) directed against GD2 are used as part of post-consolidation treatment for high-risk neuroblastoma (NB) patients with minimal residual tumor after induction therapy. It has been reported that a good end-of-induction response is associated with better event-free survival and overall survival rates. The use of mAbs in combination with chemotherapy has been shown to be effective in treating patients with relapsed NB in several international studies. Thus, the need to achieve a good end-of-induction response in high-risk NB and the feasibility of combining chemotherapy with mAbs serve as a rationale for employing immunotherapy during induction treatment of newly diagnosed patients with NB. Here, we present the results of the first Russian single-center study on the use of chemoimmunotherapy (CIT) during induction treatment in newly diagnosed patients with high-risk NB. In this prospective study carried out at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between January and August 2023, we enrolled 5 high-risk stage 4 NB patients aged 18 months. This study was approved by the Institutional Review Board and the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Healthcare of the Russian Federation (Protocol No. 10э/9-22 dated 10. 12. 2022). Therapy was carried out according to the modified GPOH NB2004 protocol. Starting from the 3rd course of induction, patients received 4 alternating courses of chemotherapy in combination with anti-G mAbs ch14.18/CHO (dinutuximab beta) at a dose of 10 mg/m2/day administered as a continuous infusion over 5 days. Toxicity was assessed as per the CTCAE 5.0 (Common Terminology Criteria for Adverse Events, version 5.0). A total of 20 courses of CIT were given. All patients completed induction therapy, with 3/5 (60%) achieving at least a partial response. There were no cases of unexpected severe toxicity or death. There were no pauses in the administration of mAb throughout all the CIT cycles, and all the patients received dinutuximab beta at full dose. Grade 3/4 toxicity was predominantly hematological. Non-hematological toxicity of grade ≥ III/IV included hypokalemia in 5/20 (25 %) courses, hypertension in 4/20 (20 %) courses and diarrhea in 3/20 (15 %) courses (due to viral infection). The need for opioid analgesics decreased with each successive course of treatment. The selected CIT regimen combining induction chemotherapy as per the GPOH NB2004 protocol and dinutuximab beta demonstrated safety and acceptable toxicity in newly diagnosed patients with high-risk stage 4 NB older than 18 months. Further multicenter cooperative studies will allow for the development of the optimal induction regimen consisting of chemotherapy and mAbs for improved survival in patients with high-risk NB.

29 October 2024 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
TST. V. Shamanskaya
T. V. Shamanskaya
VPVassilios Papadakis
Vassilios Papadakis
DUD. T. Utalieva
D. T. Utalieva
GNG. V. Nikolaev
G. V. Nikolaev
OZO. S. Zaсarinnaya
O. S. Zaсarinnaya
DKDenis Kachanov
Denis Kachanov
Introduction. The results of treatment of high-risk neuroblastoma (NB) patients at the current stage remain unsatisfactory and overall survival does not exceed 50–60 %. Response to induction therapy, including response from distant metastases, is an important prognostic factor. Worse treatment outcomes are noted in patients who have not achieved complete resolution of metastatic foci. Intensification of postconsolidation therapy with the addition of cytostatic drugs not used at the induction treatment stage to 13-cis-retinoic acid (13-cis-RA) is a possible treatment option aimed at overcoming tumor cell resistance and improving both objective response and long-term prognosis in these patients.Materials and methods. We conducted a multicenter prospective study of the use of 12 courses of temozolomide in combination with 9 courses of 13-cis-RA as part of postconsolidation therapy in high-risk NB patients who achieved an unsatisfactory response to induction therapy (persistence of metastatic foci) within the modified protocol of German Society for Pediatric Oncology and Hematology GPOH NB-2004, who received this therapy from January 2020 to January 2022. Temozolomide therapy was administered at a dosage of 150 mg/m2/day per os (intravenous administration was allowed) for 5 days and started on day 29 of the first cycle of 13-cis-RA. Another course of 13-cisRA was started on day 6 of temozolomide administration. During the 3-month break between the courses of 13-cis-RA (6 and 7 courses), temozolomide was continued for 5 days (the courses were repeated every 28 days).Results. Fourteen high-risk NB patients with a median age at the time of diagnosis of 62 months (range – 9–173 months) were included in the study. Thirteen patients with newly diagnosed NB were verified with INSS stage 4 disease and INRGSS stage M; 1 patient with initial localized low-risk NB subsequently developed a combined relapse. 9/14 (64 %) patients received standard induction therapy and 5/14 (36 %) received intensified therapy due to an unfavorable response to the first six courses of induction chemotherapy. The response after completion of induction therapy was evaluated as partial response (PR) in 6/14 patients, mixed response (MR) in 6/14, and stable disease (SD) in 2/14. All patients received high-dose chemotherapy and autologous hematopoietic stem cell transplantation (auto-HSCT) during the consolidation phase. Postconsolidation therapy included a total of 134 cycles of temozolomide. Postconsolidation therapy including 12 cycles of temozolomide was completed by 10/14 (71 %) patients. 4/14 (28 %) patients did not complete therapy (2/4 – parental refusal of therapy and 2/4 – progression (PR)). 4/14 (29 %) patients included in the study fully completed the proposed regimen of post-consolidation therapy (13-cis-RA and temozolomide) without the addition of other therapeutic agents. 6/14 (43 %) patients received all 12 courses of temozolomide in combination with anti-GD2 targeted monoclonal antibodies (mAbs) immunotherapy and/or molecularly targeted therapy. In 3/14 (21 %) patients, manifestations of hematologic toxicity were observed, requiring reduction of temozolomide dosage and increasing the course interval. One out of 3 patients experienced thrombocytopenia on courses 2–5 and 2 out of 3 patients experienced grade II–III neutropenia on courses 5 and 2, 6, respectively. No unexpected serious toxicities, including deaths, were reported during all courses evaluated. Overall, 11/14 (79 %) patients completed first-line therapy (complete response (CR) – 2/11, PR – 7/11, SD – 1/11, PR – 1/11), 3/14 (21 %) did not complete due to disease progression. Currently, 11/14 (79 %) patients are alive (3/11 – after PR/relapse and 8/11 – alive without events). 2/14 (14 %) patients died from disease progression, 1/14 (7 %) – from non-tumor related causes. Median follow-up from diagnosis was 39.3 months for all patients (range – 12.5–62.5) and 42.5 months for survivors (range – 24.4–62.5).Conclusions. For high-risk NB patients who have not achieved a complete metastatic response to the induction therapy phase, intensification of the postconsolidation phase of treatment may be suggested. The addition of temozolomide to the differentiation agent 13-cis-RA in our study demonstrated minimal toxicity, good tolerability, and improved response in a subset of patients. Further studies are needed to select the optimal regimen of postconsolidation therapy for patients with an unsatisfactory response to the induction phase.

30 September 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
TST. V. Stradomskaya
T. V. Stradomskaya
ASAmina Suleymanova
Amina Suleymanova
DKD. M. Konovalov
D. M. Konovalov
ADAlexander E. Druy
Alexander E. Druy
APA. V. Panfyorova
A. V. Panfyorova
DKDenis Kachanov
Denis Kachanov
Somatic translocations involving the NTRK genes occur in 0.34–2.2% of all malignant neoplasms in children. TRK inhibitors whose efficacy has been demonstrated in prospective clinical studies expand treatment options for patients with solid tumors harboring NTRK gene rearrangements. The aim of our study was to summarize the first Russian experience with the use of the TRK inhibitor entrectinib in patients with extracranial NTRK fusion-positive solid tumors included in the compassionate use program. This study was approved by the Independent Ethics Committee and the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included 8 patients who had been treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and the N.N. Blokhin National Medical Research Center of Oncology. The main criteria for inclusion in the compassionate use program were a confirmed rearrangement of either NTRK1/2/3 genes in a solid tumor in patients with unresectable disease for whom no effective standard systemic therapy was available, progressive or recurrent disease during therapy prescribed according to the established diagnosis, risk group and risk stratification criteria, and the infeasibility of non-mutilating radical surgery. The median age at diagnosis was 4.3 months (range 1.2–83.6). The male to female ratio was 1:1. The primary site distribution was as follows: head and neck (n = 6; 75%), chest wall (n = 1; 12.5%), pelvis (n = 1; 12.5%). None of the patients had regional lymph node involvement or distant metastases at diagnosis. The distribution by histology (according to histopathology reports) was as follows: infantile fibrosarcoma (n = 4; 50%), undifferentiated round cell sarcoma, low-grade (n = 1; 12.5%), undifferentiated spindle cell sarcoma, high-grade (n = 1; 12.5%), NTRK-rearranged spindle cell sarcoma, low-grade (n = 1; 12.5%), spindle cell tumor associated with an NTRK rearrangement (n = 1; 12.5%). Immunohistochemistry (IHC) with a pan-Trk monoclonal antibody was performed in 7/8 (87.5%) patients. Pan-Trk IHC was positive in 4/7 (57%) patients. Rearrangements in the NTRK1 and NTRK3 genes were confirmed in all the patients. The final methods used for the detection of fusion transcripts were as follows: reverse transcription polymerase chain reaction (n = 4; 50%) and RNA-based next-generation sequencing (n = 4; 50%). NTRK1 and NTRK3 gene translocations were detected in 3/8 (37.5%) and 5/8 (62.5%) patients, respectively. The following fusion transcripts were identified: ETV6::NTRK3 (n = 4), DIP2C::NTRK3 (n = 1), TPR::NTRK1 (n = 1), TPM3::NTRK1 (n = 1), MYH10::NTRK1 (n = 1). One (12.5%) patient received entrectinib as first-line therapy, other patients (7/8, 87.5%) received entrectinib as secondor subsequent-line therapy. Three (37.5%) patients had undergone surgery before treatment with entrectinib: 2 had R2 resection, 1 had R0/R1 resection (resection margins were not evaluated). None of the patients received radiation therapy. The median duration of entrectinib therapy at the time of analysis was 11.8 months (range 2.3–20.1). Delayed surgery was performed in 2/8 patients; according to the histopathology reports, they achieved grade IV pathomorphosis. Three patients experienced adverse events during treatment with entrectinib. The median time to adverse events was 0.23 months (range 0.2–7.96). Three patients required temporary interruption in treatment to relieve symptoms, a subsequent dose reduction by one dose level was necessary when resuming therapy in two patients. The median follow-up since diagnosis was 19.5 months (range 14.9–75.0). All the patients included in our analysis were alive, three of them had no radiologic evidence of disease. Fifty percent of the patients completed targeted therapy, another 50% of the patients continued treatment with entrectinib. Complete and very good partial response was achieved in 3/8 and 2/8 patients, respectively. Partial response, minor partial response and stable disease were observed in one patient each. These results indicate high efficacy and safety of entrectinib in pediatric patients with extracranial NTRK fusion-positive solid tumors. Further studies are needed to determine the therapeutic potential of TRK inhibitors in the treatment of different solid malignant neoplasms in children and to assess long-term treatment results.

20 December 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
OZO. S. Zatsarinnaya
O. S. Zatsarinnaya
MTM. A. Toporkov
M. A. Toporkov
NANataliya A. Andreeva
Nataliya A. Andreeva
MTM. V. Teleshova
M. V. Teleshova
DUD. T. Utalieva
D. T. Utalieva
DKDenis Kachanov
Denis Kachanov
Angiosarcoma is a rare and highly malignant endothelial tumor, which occurs mainly in adults and is extremely rare in children and adolescents. The German guidelines for the treatment of soft tissue sarcomas provided by the Cooperative Weichteilsarkom Studiengruppe in 2012 included a separate therapeutic regimen for pediatric angiosarcoma consisting of a combination of vincristine/doxorubicin/cyclophosphamide (VDC) and paclitaxel. The aim of this article was to describe the epidemiological, clinical, and morphological characteristics of angiosarcoma, to review treatment approaches, and to present the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation in the treatment of children with angiosarcoma. Our study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. The study included 5 patients diagnosed with angiosarcoma who had received treatment between 2012 and 2022. The patients’ parents gave consent to the use of their child's data, including photographs, for research purposes and in publications. Data on the patients’ age, gender, tumor location and extension, performed treatment and outcomes of the disease were analyzed. The male:female ratio was 0.66:1 and the median age was 5.2 years. Tumors were located in the soft tissues (n = 3) and in the bones (n = 2). In all the cases, invasion of the surrounding tissues was observed. There were no distant metastases at the time of diagnosis. Two (40%) patients underwent primary resection (R1) and 3 (60%) patients had tumor biopsy. Four patients received therapy according to the German guidelines for the treatment of angiosarcoma (VDC/paclitaxel courses), and 1 patient received treatment according to the guidelines for the management of non-rhabdomyosarcoma soft-tissue sarcomas (courses with vincristine, ifosfamide, doxorubicin/ vincristine, ifosfamide, actinomycin D). Objective response to treatment was achieved in 3 (60%) cases. Local control treatment of these 3 patients consisted of radiation therapy with a total dose of 50.4 Gy after R1 resection in 2 cases and biopsy in 1 case. After a median follow-up of 32 months, 2 patients who had received VDC/paclitaxel were alive without events (with complete and partial response), 3 patients died of progressive disease. Our data confirm the aggressive behavior of angiosarcoma in children. Protocol therapy that includes multiagent chemotherapy based on paclitaxel and doxorubicin along with local control treatment makes it possible to achieve a long-term control of the disease in some patients. However, further research on molecular and genetic characteristics of angiosarcoma is required to find potential novel targets for molecular targeted therapy. Further studies investigating the effectiveness of checkpoint inhibitors in angiosarcoma are also needed.

20 December 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
VDV. A. Denisov
V. A. Denisov
AGA. Z. Gasieva
A. Z. Gasieva
OZO. S. Zatsarinnaya
O. S. Zatsarinnaya
DKDenis Kachanov
Denis Kachanov
IKI. G. Khamin
I. G. Khamin
Cardiac tamponade, characterized by slowly or rapidly developing compression (by fluid, blood, pus or gas) that prevents the heart chambers from filling with blood is one of the most dangerous complications associated with the aggressive growth of intrathoracic malignant tumors, including cardiac tumors. Clinical manifestations of this complication may include tachycardia, progressive hypotension, elevated jugular venous pressure and pulsus paradoxus (a symptom characterized by a decrease in systolic blood pressure by more than 10 mmHg during inspiration). In the present article, we report a clinical case of a patient with rhabdomyosarcoma of the heart complicated by cardiac tamponade. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications.

13 December 2025 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ABAnna V. Bykova
Anna V. Bykova
NANataliya A. Andreeva
Nataliya A. Andreeva
ROR. S. Oganesyan
R. S. Oganesyan
ISIlya Sidorov
Ilya Sidorov
NIN. S. Ivanov
N. S. Ivanov
TST. V. Shamanskaya
T. V. Shamanskaya
Introduction. Over the past two decades, immunotherapy has become the standard of treatment for some solid malignancies in children including neuroblastoma (NB). It is a relatively safe treatment modality if appropriate supportive care is provided. However, like other treatments, immunotherapy can result in a unique toxicity profile that requires timely interpretation and appropriate management. One of the described side effects is eosinophilia that in some cases can be accompanied by adverse events affecting various organs and systems. Mechanisms of injury, critical target organs, and approaches to management are still understudied. Aim – to study the relationship between increased peripheral blood eosinophil counts and adverse events including clinical symptoms of acute tonsillitis developing during immunotherapy with dinutuximab beta in patients with NB. Being a retrospective analysis, this study did not require approval from the local Ethics Committee. Materials and methods. We retrospectively analyzed the medical history and clinical and laboratory data of 40 patients with NB who had undergone immunotherapy with dinutuximab beta as first- or second-line treatment at the Dmitry Rogachev National Medical Research Center from 2019 to 2023. Results. Eosinophilia was seen to develop between immunotherapy cycles and was accompanied by skin reactions in 47.5% of cases (in 19/40 patients) and by itchiness (14/40), bronchial obstruction syndrome (14/40) or acute tonsillitis (14/40) – in 35% of cases. From сycle to cycle, there was a tendency towards a decrease in maximum absolute eosinophil count as well as in the incidence of itchiness. At the same time, skin reactions and acute tonsillitis developed almost as frequently in the following cycles. A comparison of clinical symptoms with laboratory data revealed that eosinophilia was significantly correlated only with acute tonsillitis (p 0.05). In this study, we investigated potential causes of this condition. We reported a clinical case of acute tonsillitis that had developed during immunotherapy with dinutuximab beta confirming the hypothesis about the potential infiltration of the tonsils by eosinophils. Conclusions. One of the side effects of immunotherapy with dinutuximab beta in NB patients is non-infectious tonsillitis which can be confirmed by a histological analysis showing morphological features of eosinophilic infiltration of the palatine tonsils. A differential diagnosis between this condition and infections as well as careful monitoring of patients treated with dinutuximab beta is required for timely identification and correct interpretation of adverse reactions.